Related Experiment Video
Updated: Aug 4, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Transforming growth factor-beta administration modifies cyclosporine A-induced bone loss
G R Goodman1, I R Dissanayake, A R Bowman
1Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA.
Bone
|June 27, 2001
Summary
Cyclosporine A (CsA) causes bone loss, but administering transforming growth factor-beta (TGF-beta) may counteract these effects. TGF-beta appears to protect bone by increasing osteoblast activity when given with CsA.
Area of Science:
- Pharmacology
- Bone Biology
- Immunosuppression
Background:
- Cyclosporine A (CsA) is a vital immunosuppressant in transplantation.
- CsA is known to cause osteopenia by increasing bone resorption and formation.
- Transforming growth factor-beta (TGF-beta) influences bone remodeling and may be implicated in CsA's side effects.
Purpose of the Study:
- To investigate if exogenous TGF-beta administration can mitigate the negative bone effects of CsA.
- To explore the interaction between TGF-beta and CsA on bone metabolism.
Main Methods:
- Male Sprague-Dawley rats were assigned to four groups: TGF-beta + CsA vehicle, TGF-beta + CsA, TGF-beta vehicle + CsA, and control.
- Animals received treatments over 28 days.
- Bone metabolism markers, including serum 1,25(OH)(2)D and osteocalcin, were measured. Histomorphometry was used to assess bone formation and resorption parameters.
Main Results:
- CsA increased serum 1,25(OH)(2)D and osteocalcin (BGP) levels, while TGF-beta alone had no significant effect.
- Co-administration of TGF-beta with CsA counteracted CsA's effect on osteocalcin.
- Histomorphometry revealed that TGF-beta blocked CsA's detrimental effects and enhanced osteoblast recruitment and activity, increasing bone formation rates.
Conclusions:
- Exogenous TGF-beta administration shows potential in modulating the deleterious bone effects associated with CsA treatment.
- TGF-beta may offer a protective strategy against CsA-induced osteopenia by promoting bone formation.
Related Concept Videos
01:40Bone Remodeling
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...